DexCom, Inc. vs Jabil Inc — how do they compare? DexCom, Inc. trades at $89.27 (market cap $33.79B), while Jabil Inc trades at $366.75 (market cap $37.37B). The key difference: DexCom, Inc. and Jabil Inc are close in size by market cap, and Jabil Inc pays a 0.09% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | JBL | |
|---|---|---|
Market Cap | $33.79B | $37.37B |
Sector | Health | Technology |
52-Week High | $89.53 | $385.50 |
52-Week Low | $54.84 | $192.49 |
Enterprise Value | $33.24B | $39.90B |
Dividend Yield | — | 0.09% |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →